Bladder cancer in males

A comprehensive review of urothelial carcinoma of the bladder

Christopher R. Murphy, Robert Jeffrey Karnes

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bladder cancer is the second most common genitourinary malignancy after prostate cancer. It is a disease most commonly encountered in the elderly, particularly males, and has several well-established risk factors, including smoking and occupational exposures to certain chemical carcinogens. Roughly 90% of all bladder cancers are urothelial in origin; that is, they arise from the epithelial lining of the bladder. The remainder, including squamous cell carcinoma and adenocarcincoma, are nonurothelial. This review will focus solely on bladder cancer of urothelial origin, commonly referred to as urothelial carcinoma (UC) of the bladder. Bladder cancer can be divided into three distinct clinical entities: nonmuscle-invasive bladder cancer (NMIBC), muscleinvasive bladder cancer (MIBC), and metastatic bladder cancer. Each entity calls for different management. NMIBC, which accounts for roughly 70% of bladder cancer diagnoses, usually can be managed with transurethral resection, intravesical chemotherapy/immunotherapy, and aggressive surveillance protocols to monitor for recurrence and progression. MIBC calls for radical cystectomy (RC) with urinary diversion and bilateral pelvic lymph node dissection. Although it is often underutilized, neoadjuvant chemotherapy with platinumbased regimens improves survival. Data on adjuvant chemotherapy are less robust, but it remains an option for those who are medically fit and considered to be at high risk for recurrence and progression. Bladder-preserving strategies, including partial cystectomy and trimodality therapy, can provide adequate cancer control in appropriately selected patients with MIBC. Stringent surveillance is required. Metastatic bladder cancer is often lethal and the standard of care remains platinum-based chemotherapy regimens. Renal insufficiency is a common comorbidity that prevents patients from receiving chemotherapy in all settings. Currently, there are no recommended second-line chemotherapy regimens. Given the high rate of recurrence and progression, better prognostic variables should help to identify those who should be targeted in clinical trials. As bladder cancer affects a large number of men every year and significantly contributes to healthcare expenditures, prompt diagnosis and appropriate management are critical.

Original languageEnglish (US)
Pages (from-to)18-27
Number of pages10
JournalJournal of Men's Health
Volume11
Issue number1
DOIs
StatePublished - Mar 1 2014

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Carcinoma
Drug Therapy
Cystectomy
Recurrence
Urinary Diversion
Occupational Exposure
Adjuvant Chemotherapy
Standard of Care
Health Expenditures
Platinum
Lymph Node Excision
Carcinogens
Immunotherapy
Renal Insufficiency
Comorbidity
Squamous Cell Carcinoma
Neoplasms
Prostatic Neoplasms

Keywords

  • Bladder cancer
  • Metastatic bladder cancer
  • Muscle-invasive bladder cancer
  • Nonmuscle-invasive bladder cancer
  • review
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Medicine(all)
  • Urology

Cite this

Bladder cancer in males : A comprehensive review of urothelial carcinoma of the bladder. / Murphy, Christopher R.; Karnes, Robert Jeffrey.

In: Journal of Men's Health, Vol. 11, No. 1, 01.03.2014, p. 18-27.

Research output: Contribution to journalArticle

@article{550e49073aec4d7f9b6e9bfe414150ad,
title = "Bladder cancer in males: A comprehensive review of urothelial carcinoma of the bladder",
abstract = "Bladder cancer is the second most common genitourinary malignancy after prostate cancer. It is a disease most commonly encountered in the elderly, particularly males, and has several well-established risk factors, including smoking and occupational exposures to certain chemical carcinogens. Roughly 90{\%} of all bladder cancers are urothelial in origin; that is, they arise from the epithelial lining of the bladder. The remainder, including squamous cell carcinoma and adenocarcincoma, are nonurothelial. This review will focus solely on bladder cancer of urothelial origin, commonly referred to as urothelial carcinoma (UC) of the bladder. Bladder cancer can be divided into three distinct clinical entities: nonmuscle-invasive bladder cancer (NMIBC), muscleinvasive bladder cancer (MIBC), and metastatic bladder cancer. Each entity calls for different management. NMIBC, which accounts for roughly 70{\%} of bladder cancer diagnoses, usually can be managed with transurethral resection, intravesical chemotherapy/immunotherapy, and aggressive surveillance protocols to monitor for recurrence and progression. MIBC calls for radical cystectomy (RC) with urinary diversion and bilateral pelvic lymph node dissection. Although it is often underutilized, neoadjuvant chemotherapy with platinumbased regimens improves survival. Data on adjuvant chemotherapy are less robust, but it remains an option for those who are medically fit and considered to be at high risk for recurrence and progression. Bladder-preserving strategies, including partial cystectomy and trimodality therapy, can provide adequate cancer control in appropriately selected patients with MIBC. Stringent surveillance is required. Metastatic bladder cancer is often lethal and the standard of care remains platinum-based chemotherapy regimens. Renal insufficiency is a common comorbidity that prevents patients from receiving chemotherapy in all settings. Currently, there are no recommended second-line chemotherapy regimens. Given the high rate of recurrence and progression, better prognostic variables should help to identify those who should be targeted in clinical trials. As bladder cancer affects a large number of men every year and significantly contributes to healthcare expenditures, prompt diagnosis and appropriate management are critical.",
keywords = "Bladder cancer, Metastatic bladder cancer, Muscle-invasive bladder cancer, Nonmuscle-invasive bladder cancer, review, Urothelial carcinoma",
author = "Murphy, {Christopher R.} and Karnes, {Robert Jeffrey}",
year = "2014",
month = "3",
day = "1",
doi = "10.1089/jomh.2014.3503",
language = "English (US)",
volume = "11",
pages = "18--27",
journal = "Journal of Men's Health and Gender",
issn = "1875-6867",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Bladder cancer in males

T2 - A comprehensive review of urothelial carcinoma of the bladder

AU - Murphy, Christopher R.

AU - Karnes, Robert Jeffrey

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Bladder cancer is the second most common genitourinary malignancy after prostate cancer. It is a disease most commonly encountered in the elderly, particularly males, and has several well-established risk factors, including smoking and occupational exposures to certain chemical carcinogens. Roughly 90% of all bladder cancers are urothelial in origin; that is, they arise from the epithelial lining of the bladder. The remainder, including squamous cell carcinoma and adenocarcincoma, are nonurothelial. This review will focus solely on bladder cancer of urothelial origin, commonly referred to as urothelial carcinoma (UC) of the bladder. Bladder cancer can be divided into three distinct clinical entities: nonmuscle-invasive bladder cancer (NMIBC), muscleinvasive bladder cancer (MIBC), and metastatic bladder cancer. Each entity calls for different management. NMIBC, which accounts for roughly 70% of bladder cancer diagnoses, usually can be managed with transurethral resection, intravesical chemotherapy/immunotherapy, and aggressive surveillance protocols to monitor for recurrence and progression. MIBC calls for radical cystectomy (RC) with urinary diversion and bilateral pelvic lymph node dissection. Although it is often underutilized, neoadjuvant chemotherapy with platinumbased regimens improves survival. Data on adjuvant chemotherapy are less robust, but it remains an option for those who are medically fit and considered to be at high risk for recurrence and progression. Bladder-preserving strategies, including partial cystectomy and trimodality therapy, can provide adequate cancer control in appropriately selected patients with MIBC. Stringent surveillance is required. Metastatic bladder cancer is often lethal and the standard of care remains platinum-based chemotherapy regimens. Renal insufficiency is a common comorbidity that prevents patients from receiving chemotherapy in all settings. Currently, there are no recommended second-line chemotherapy regimens. Given the high rate of recurrence and progression, better prognostic variables should help to identify those who should be targeted in clinical trials. As bladder cancer affects a large number of men every year and significantly contributes to healthcare expenditures, prompt diagnosis and appropriate management are critical.

AB - Bladder cancer is the second most common genitourinary malignancy after prostate cancer. It is a disease most commonly encountered in the elderly, particularly males, and has several well-established risk factors, including smoking and occupational exposures to certain chemical carcinogens. Roughly 90% of all bladder cancers are urothelial in origin; that is, they arise from the epithelial lining of the bladder. The remainder, including squamous cell carcinoma and adenocarcincoma, are nonurothelial. This review will focus solely on bladder cancer of urothelial origin, commonly referred to as urothelial carcinoma (UC) of the bladder. Bladder cancer can be divided into three distinct clinical entities: nonmuscle-invasive bladder cancer (NMIBC), muscleinvasive bladder cancer (MIBC), and metastatic bladder cancer. Each entity calls for different management. NMIBC, which accounts for roughly 70% of bladder cancer diagnoses, usually can be managed with transurethral resection, intravesical chemotherapy/immunotherapy, and aggressive surveillance protocols to monitor for recurrence and progression. MIBC calls for radical cystectomy (RC) with urinary diversion and bilateral pelvic lymph node dissection. Although it is often underutilized, neoadjuvant chemotherapy with platinumbased regimens improves survival. Data on adjuvant chemotherapy are less robust, but it remains an option for those who are medically fit and considered to be at high risk for recurrence and progression. Bladder-preserving strategies, including partial cystectomy and trimodality therapy, can provide adequate cancer control in appropriately selected patients with MIBC. Stringent surveillance is required. Metastatic bladder cancer is often lethal and the standard of care remains platinum-based chemotherapy regimens. Renal insufficiency is a common comorbidity that prevents patients from receiving chemotherapy in all settings. Currently, there are no recommended second-line chemotherapy regimens. Given the high rate of recurrence and progression, better prognostic variables should help to identify those who should be targeted in clinical trials. As bladder cancer affects a large number of men every year and significantly contributes to healthcare expenditures, prompt diagnosis and appropriate management are critical.

KW - Bladder cancer

KW - Metastatic bladder cancer

KW - Muscle-invasive bladder cancer

KW - Nonmuscle-invasive bladder cancer

KW - review

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84978147663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978147663&partnerID=8YFLogxK

U2 - 10.1089/jomh.2014.3503

DO - 10.1089/jomh.2014.3503

M3 - Article

VL - 11

SP - 18

EP - 27

JO - Journal of Men's Health and Gender

JF - Journal of Men's Health and Gender

SN - 1875-6867

IS - 1

ER -